Morgan Stanley assumed coverage of Ultragenyx (RARE) with an Overweight rating and $64 price target The firm sees continued strong Crysvita growth, with Latin America representing the largest growth opportunity, while the pipeline continues to advance, representing further potential upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline
- Optimistic Outlook for Ultragenyx Pharmaceutical Amid Promising Gene Therapy Developments
- Ultragenyx’s BLA for UX111 accepted by FDA for priority review
- Ultragenyx price target raised to $136 from $121 at Canaccord
- 3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts